Pipeline
Through in-house discovery and strategic in-licensing with global best-in-class partners, we are accelerating the development and delivery of breakthrough medicines to patients around the world.
Brii Bio is building a pipeline of more than 10 novel therapeutic candidates that allows the Company to develop differentiated treatment options for patients based on two key methods:
Hepatitis B
Hepatitis B
BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination
BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination
BRII-179 (VBI-2601)
- Phase 2 development.
- BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that is being evaluated as a potential functional cure for HBV.
- Based on a licensing agreement with VBI Vaccines, Brii Bio has the exclusive rights to develop and commercialize BRII-179 in Greater China.
BRII-835 (VIR-2218)
- Phase 2 development.
- BRII-835 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV.
- Based on a licensing agreement with Vir Biotechnology, Brii Bio has the exclusive rights to develop and commercialize BRII-835 in Greater China.
Hepatitis B
BRII-179 (VBI-2601)/PEG-IFN-α Combination
BRII-179 (VBI-2601)
- Phase 2 development.
- BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that is being evaluated as a potential functional cure for HBV.
- Based on a licensing agreement with VBI Vaccines, Brii Bio has the exclusive rights to develop and commercialize BRII-179 in Greater China.
Hepatitis B
BRII-877 (VIR-3434)(1)
BRII-877 (VIR-3434)
- Phase 2 development.
- BRII-877 is an investigational subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and to reduce the level of virions and subviral particles in the blood.
- Based on a licensing agreement with Vir Biotechnology, Brii Bio has the exclusive rights to develop and commercialize BRII-877 in Greater China.
HIV
HIV
BRII-732
BRII-732
- Phase 1 development.
- BRII-732 is a new chemical entity (NCE) that, upon oral administration, is a proprietary prodrug that is metabolized into the active moiety islatravir, an investigational candidate being studied to treat and prevent HIV infection. BRII-732 is being developed as part of a potential once-weekly, combination therapy with BRII-778 to treat HIV-1.
- Internally discovered.
HIV
BRII-753
BRII-753
- Preclinical stage.
- BRII-753 is a new chemical entity, which is being developed as a long-acting subcutaneous injection with potential for dosing QM to Q6M (once monthly to once every six months). BRII-753 can be used in a combination therapy for HIV treatment and a monotherapy for PrEP (pre-exposure prophylaxis).
- Internally discovered.
MDR/XDR Gram-negative Bacterial Infections
MDR/XDR Gram-negative Bacterial Infections
BRII-672 (ORAvance)(2)
BRII-672 (ORAvance)
- Phase 1 development.
- BRII-672, a prodrug of BRII-636, is an oral beta-lactamase inhibitor in development for the treatment of multidrug- and extensively drug-resistant (MDR/XDR) Gram-negative bacterial infections.
- Based on a licensing agreement with Qpex Biopharma, Brii Bio has the exclusive rights to develop and commercialize BRII-672 in Greater China.
MDR/XDR Gram-negative Bacterial Infections
BRII-693 (QPX9003)(2)
BRII-693 (QPX9003)
- Phase 1 development.
- BRII-693 is a novel synthetic lipopeptide in development for the treatment of multidrug- and extensively drug-resistant (MDR/XDR) Gram-negative bacterial infections.
- Based on a licensing agreement with Qpex Biopharma, Brii Bio has the exclusive rights to develop and commercialize BRII-658 in Greater China.
MDR/XDR Gram-negative Bacterial Infections
BRII-636 (OMNIvance)(2)
BRII-636 (OMNIvance)
- Phase 1 development.
- BRII-636 is novel cyclic boronic acid derived broad-spectrum inhibitor in development for the treatment of multidrug- and extensively drug-resistant (MDR/XDR) Gram-negative bacterial infections.
- Based on a licensing agreement with Qpex Biopharma, Brii Bio has the exclusive rights to develop and commercialize BRII-636 in Greater China.
NTM Lung Disease
NTM Lung Disease
BRII-658 (Epetraborole)(3)
BRII-658
- Phase 2 development.
- BRII-658 is in development as a once-daily oral treatment for patients with chronic nontuberculous mycobacterial (NTM) lung disease, with an initial focus on treatment of refractory mycobacterium avium complex (MAC) lung disease.
- Based on a licensing agreement with AN2 Therapeutics, Brii Bio has the exclusive rights to develop and commercialize BRII-658 in Greater China.
PPD
PPD
BRII-296
PPD
- Phase 1 completion.
- BRII-296 is a novel, single injection therapeutic candidate in development for the treatment postpartum depression (PPD) . It acts as a gamma-aminobutyric acid A (GABAa) receptor positive allosteric modulator (PAM) and is designed to provide a rapid, profound and sustained reduction in depressive symptoms of PPD with the potential to lead to greater adherence, convenience and fewer side effects compared to the current standard of care.
- Internally discovered.
Anxiety & Other Depressive Disorders
Anxiety & Other Depressive Disorders
BRII-296
Anxiety & Other Depressive Disorders
- Phase 1 completion.
- Phase 1 development of BRII-296 in other indications has been completed.
- Internally discovered.
Anxiety & Depressive Disorders
Anxiety & Depressive Disorders
BRII-297
BRII-297
- IND filed.
- BRII-297 is a new chemical entity under development for the treatment of various anxiety and depressive disorders.
- Internally discovered.
*Greater China – Mainland China, Macau, Hong Kong and Taiwan
Source: Company information
(1) The Phase 2 clinical trials have been conducted by VIR
(2) To this date, the development and clinical trials have been conducted by Qpex
(3) To this date, the development and clinical trials have been conducted by AN2
Partners
We are working with global best-in-class partners to advance our shared vision of delivering innovative and meaningful treatment options to patients. Our strategic partnerships optimize the unique strengths and capabilities of each entity in order rapidly transform cutting-edge science and address patient needs.
